

The Role of Pancreatic Enzyme Insufficiency in the Etiology of Functional Dyspepsia Resistant to Standard Treatment

Fatih Kemik 

Department of Internal Medicine, İstanbul University İstanbul Medical School, İstanbul, Türkiye

Cite this article as: Kemik F. The role of pancreatic enzyme insufficiency in the etiology of functional dyspepsia resistant to standard treatment. *Turk J Gastroenterol.* 2026;37(1):144-145.

Dear Editor,

We would like to thank the correspondent for their thoughtful comments on our article entitled "The Role of Pancreatic Enzyme Insufficiency in the Etiology of Functional Dyspepsia Resistant to Standard Treatment." We appreciate the opportunity to further clarify several aspects of our methodology and findings.

We acknowledge that the relatively small cohort size represents a limitation of our study. As stated in the discussion, this was the largest cohort-based analysis on this topic in our region; nevertheless, we agree that larger, multicenter, population-based studies are needed. Regarding statistical testing, we prioritized a descriptive and exploratory approach to generate hypotheses.¹ While adjustments for multiplicity were not applied, our findings are consistent with previous reports, and we believe they still provide useful clinical signals warranting further investigation.

The concern regarding the inclusion of diabetic patients is well taken. Indeed, exocrine pancreatic insufficiency (EPI) is more common in patients with diabetes.^{2,3} However, this reflects real-world clinical practice: patients with both dyspeptic symptoms and diabetes are frequently encountered, and the differentiation between functional dyspepsia (FD) and diabetes-associated EPI is challenging. For this reason, we performed subgroup analyses and demonstrated that the prevalence of EPI was significantly higher in FD patients with DM (diabetes mellitus) compared to those without DM. Rather than confounding, we consider this an important clinical message that clinicians should maintain heightened awareness of possible EPI in dyspeptic patients with diabetes.

We agree that the Rome IV criteria classify patients with active *Helicobacter pylori* infection as "Hp-associated

dyspepsia" rather than FD.^{4,5} In our study, all patients underwent upper endoscopy and histological evaluation; those with organic pathologies were excluded. Patients with Hp infection were treated according to national guidelines, and only those with persistent symptoms after standard therapy (defined as at least 4 weeks of proton pump inhibitors, prokinetics, and, when required, low-dose antidepressants) were considered within the FD framework. Of note, none of the patients with EPI in our cohort were Hp positive, which further strengthens the association between EPI and refractory FD.

We concur that our results should be interpreted with caution, yet they highlight an underappreciated overlap between FD and EPI.⁶ We hope that our study stimulates larger, multicenter investigations that will refine the diagnostic pathways for dyspeptic patients. We thank the correspondent for underscoring the clinical importance of this topic and for contributing to a constructive academic dialogue.

Sincerely,

Fatih Kemik, MD

on Behalf of the Authors

Data Availability Statement: The data that support the findings of this study are available on request from the corresponding author.

Peer-review: Externally peer-reviewed.

Author Contributions: Concept – F.K.; Design – F.K.; Supervision – F.K.; Resources – F.K.; Materials – F.K.; Data Collection and/or Processing – F.K.; Analysis and/or Interpretation – F.K.; Literature Search – F.K.; Writing – F.K.; Critical Review – F.K.

Declaration of Interests: The authors have no conflicts of interest to declare.

Corresponding author: **Fatih Kemik**, e-mail: kemikfatih41@gmail.com

Received: **September 9, 2025** Accepted: **September 11, 2025** Publication Date: **October 31, 2025**

DOI: [10.5152/tjg.2025.255322](https://doi.org/10.5152/tjg.2025.255322)

Funding: The authors declare that this study received no financial support.

REFERENCES

1. Rothman KJ. No adjustments are needed for multiple comparisons. *Epidemiology*. 1990;1(1):43-46. [\[CrossRef\]](#)
2. Mohapatra S, Majumder S, Smyrk TC, et al. Diabetes mellitus is associated with an exocrine pancreatopathy: conclusions from a review of literature. *Pancreas*. 2016;45(8):1104-1110. [\[CrossRef\]](#)
3. Demir K, Karaca C, Ahishali E, et al. A cross-sectional study to assess the prevalence of pancreatic exocrine insufficiency among diabetes mellitus patients in Turkey. *Pancreas*. 2016;45(7):e39-e40. [\[CrossRef\]](#)
4. Stanghellini V, Chan FKL, Hasler WL, et al. Gastroduodenal disorders. *Gastroenterology*. 2016;150(6):1380-1392. [\[CrossRef\]](#)
5. Suzuki H. The application of the Rome IV criteria to functional esophagogastrroduodenal disorders in Asia. *J Neurogastroenterol Motil*. 2017;23(3):325-333. [\[CrossRef\]](#)
6. Capurso G, Traini M, Piciocchi M, Signoretti M, Arcidiacono PG. Exocrine pancreatic insufficiency: prevalence, diagnosis, and management. *Clin Exp Gastroenterol*. 2019;12:129-139. [\[CrossRef\]](#)